McKesson (MCK)
Distributes medicines while powering specialty care, medication access, and pharmacy operations.
Something off on this page? Send us feedback.
Distributes pharmaceuticals across the United States and Canada, combining wholesale logistics with oncology and specialty-practice services, medication-access technology, and medical-surgical supplies. The pharmaceutical network is the core, while the Medical-Surgical business is being prepared for separation as Wellverse.
Distributes branded, generic, specialty, biosimilar, and over-the-counter medicines across the United States and Canada through North American Pharmaceutical, while providing pharmacy operations, sourcing, inventory, and clinical services. Its distribution network and technology coordinate product availability for retail chains, community pharmacies, hospitals, and health systems.
Extends beyond wholesale through Oncology & Multispecialty, which combines specialty distribution, group purchasing, community oncology and ophthalmology practice platforms, research, and technology. Prescription Technology Solutions connects patients, providers, pharmacies, payers, and biopharma around prior authorization, affordability, adherence, and third-party logistics. Medical-Surgical Solutions supplies non-acute care settings.
Depends on high-volume, tightly regulated pharmaceutical flows, controlled-substance oversight, drug-traceability rules, and manufacturer and customer relationships. Medical-Surgical remains controlled and consolidated while its planned separation as Wellverse advances.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 19, 2026 | Barclays | Reiterate | Rating: —Target: $1,050 | Target: $1,000 |
| Aug 19, 2026 | RBC Capital | Initiate | Rating: —Target: — | Target: $845 |
| Aug 11, 2026 | Wells Fargo | Reiterate | Rating: —Target: $772 | Target: $933 |
| Aug 6, 2026 | Robert W. Baird | Target | Target: $968 | Target: $1,015 |
| May 8, 2026 | UBS | Reiterate | Rating: —Target: $920 | Target: $1,050 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $5.16B · Total debt $11.70B · Total assets $88.33B · Shareholders' equity −$4.24B
- Revenue
- $105.38B
- Operating income
- $1.32B
- Net income
- $614.0M
HistoryDividendAnnual yield
| Institutions | 91.23% | 106.37M shares | |
|---|---|---|---|
| 2,081 holders · as of Jun 30, 2026 | |||
| Insiders | 0.05% | 59.0K shares | |
| 11 holders · as of Sep 10, 2026 | |||
| Other | 8.72% | 10.17M shares | |
| remainder | |||
116.59M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 9.26% | 10.80M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 6.74% | 7.85M | as of Jun 30, 2026 |
State Street CorpInstitution | 4.91% | 5.73M | as of Jun 30, 2026 |
Morgan StanleyInstitution | 4.55% | 5.31M | as of Jun 30, 2026 |
Franklin Resources IncInstitution | 2.49% | 2.91M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 8, 2026 | Napoleon B. JR Rutledge | officer: SVP, Controller & CAO | −111 | $891.45 |
| Aug 10, 2026 | Bradley E. Lerman | director | −301 | $892.33 |
| Jul 7, 2026 | Brian S. Tyler | director, officer: Chief Executive Officer | −8,463 | $793.56 |
| Jun 17, 2026 | Brian S. Tyler | director, officer: Chief Executive Officer | −8,463 | $775.13 |
| Jun 9, 2026 | Brian S. Tyler | director, officer: Chief Executive Officer | −4,929 | $763.00 |
- Cencora
Nearest Big-Three peer; same drug-distribution model at $321B revenue scale.
- Cardinal Health
Third Big-Three distributor; pharma wholesale and med-surg supply overlap.
- CVS Health
Major US PBM and pharmacy; Caremark and CVS Specialty compete on drug access.
- Cigna
Express Scripts PBM and Accredo compete on prior auth and specialty access.
- UnitedHealth Group
Optum Rx and Optum Health compete with MCK's RxTS platform and oncology network.
- Henry Schein
Alternate-site medical-surgical distributor in the same non-acute care channel.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| McKesson | $884.15 | −0.26% | $103.79B | 23.7 | 19.1 | 0.3 | +7.7% |
| Cencora | $314.12 | −0.75% | $61.58B | 23.5 | 16.2 | 0.2 | +5.1% |
| Cardinal Health | $225.29 | −0.20% | $52.87B | 31.2 | 18.0 | 0.2 | +5.8% |
| CVS Health | $87.45 | −0.17% | $111.77B | 23.2 | 10.8 | 0.3 | +7.3% |
| Cigna | $273.99 | −0.17% | $72.53B | 11.4 | 8.6 | 0.3 | +6.6% |
| UnitedHealth Group | $375.94 | −0.43% | $342.88B | 24.3 | 17.6 | 0.8 | +0.4% |
| Henry Schein | $86.13 | +1.09% | $9.71B | 24.8 | 15.2 | 0.7 | +6.7% |
| Median | 23.9 | 15.7 | 0.3 | +6.2% |